title: The effects of coenzyme A on serum lipids in patients with hyperlipidemia: results of a multicenter clinical trial.
abstract: OBJECTIVE
  The aim of the study was to evaluate the lipid-lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule, in Chinese patients with moderate dyslipidemia.
  
  
  METHODS
  A total of 244 subjects (170 males and 74 females; aged 18-75 y) having moderate dyslipidemia (triglyceride [TG], 2.3-6.5 mmol · L(-1)) were randomly divided into 3 groups, to which placebo (group A, n = 81), CoA 200 U/d (group B, n = 79), and CoA 400 U/d (group C, n = 84) were administered, respectively. Blood lipoproteins, liver and renal functions, blood glucose, and complete blood count were measured at the baseline and after 4 or 8 weeks of treatment.
  
  
  RESULTS
  After treatment for 4 weeks, TG was reduced by 5.1, 15.7, and 14.4% in groups A, B, and C, respectively. After treatment for 8 weeks, TG decreased .9, 21.7, and 36.1%, respectively. Compared with group A, the primary efficacy outcome TG in groups B and C significantly decreased (P < .01), and the difference between groups B and C was also significant (P < .01). Plasma total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were not significantly different. Furthermore, there was no difference in blood glucose, hepatic and renal function test parameters, incidence of myopathy, or gastrointestinal tract symptoms among the 3 groups.
  
  
  CONCLUSIONS
  CoA can effectively reduce plasma TG levels in subjects with moderate dyslipidemia and has no obvious adverse effect.
authors.affiliation: Cardiology Department, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China.
authors.forename: Ya-qin
authors.initials: YQ
authors.lastname: Chen
authors.forename: Shui-ping
authors.initials: SP
authors.lastname: Zhao
authors.forename: Jun-zhu
authors.initials: JZ
authors.lastname: Chen
authors.forename: Jiangtao
authors.initials: J
authors.lastname: Lai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose; D003065:Coenzyme A / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D008055:Lipids; D003065:Coenzyme A